Midnapore Medical College and Hospital is a full-fledged tertiary referral Government Medical college. It was established in the year 2004. The college imparts the degree Bachelor of Medicine and Surgery (MBBS) as well as specialised and post-doctoral degrees. Nursing and para-medical courses are also offered. The college is affiliated to West Bengal University of Health Sciences and is recognised by the National Medical Commission. The hospital associated with the college is one of the largest hospitals in the Midnapore district. The selection to the college is done on the basis of merit through National Eligibility and Entrance Test. Yearly undergraduate student intake is 200 from the year 2019..
Objectives:The study aimed to measure the prevalence of sarcopenia in male individuals with type 2 diabetes having clinically significant liver fibrosis and to identify the determinants of sarcopenia. Methods:A cross-sectional study was conducted among male individuals aged 18-65 years with type 2 diabetes and liver stiffness measurement (LSM) ≥8 kPa, as measured by transient elastography (FibroScan®). Individuals were divided into sarcopenic and nonsarcopenic groups using the 2019 Asian Working Group for Sarcopenia criteria. Results:Among 131 males with significant liver fibrosis in type 2 diabetes, 43 (32.8%) had sarcopenia. Between the sarcopenic and non-sarcopenic groups, significant differences were observed in body weight (Kg) (62.6 vs 69.7, p < 0.001) the median duration of diabetes (months) (96 vs. 60, p = 0.008), glycated hemoglobin (HbA1c, 8.8% vs. 7.9%, p = 0.007), and liver fibrosis (LSM score, 10.3 kPa vs. 9.8 kPa, p = 0.028). The adjusted odds ratios (ORs) for liver fibrosis and body weight in the development of sarcopenia were 1.165 (95% CI, 1.051-1.292) and 0.933 (95% CI, 0.894-0.974), respectively. Conclusion:Individuals with sarcopenia had a longer duration of diabetes and poorer glycemic control; lower body weight and higher grades of liver fibrosis were independent factors contributing to the same.
To determine the efficacy of intratympanic corticosteroids in late presenting (2 weeks to 6 weeks) sudden onset sensory neural hearing loss patients. Out of 45 patients, 50
Background: Prolonged waiting periods before definitive radiotherapy remain a major challenge in the management of locally advanced head and neck squamous cell carcinoma (LA-HNSCC), particularly in resource-constrained healthcare settings. Bridging systemic therapy during this interval may help maintain disease control until definitive radiotherapy can be initiated. The aim of the study was to compare the efficacy and safety of induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy with oral metronomic chemotherapy (OMCT) as bridging treatment in patients with LA-HNSCC experiencing unavoidable delays before definitive radiotherapy. Methods: A prospective randomized study was conducted in the Department of Radiotherapy, IPGME&R and SSKM Hospital, Kolkata, India, between February 2020 and November 2022. Sixty patients with biopsy-proven stage III-IVB LA-HNSCC were randomized to receive either two cycles of induction TPF chemotherapy (Arm A) or oral metronomic chemotherapy comprising weekly methotrexate and twice-daily celecoxib (Arm B) while awaiting definitive radiotherapy. Tumour response, treatment-related toxicities, disease-free survival (DFS), overall survival (OS), and quality of life were assessed. Survival outcomes were estimated using the Kaplan-Meier method. Results: Baseline demographic and clinicopathological characteristics were comparable between the two treatment groups. Induction TPF chemotherapy achieved significantly higher objective tumour response before radiotherapy and superior complete response rates following treatment compared with OMCT. Disease-free survival was significantly longer in the TPF arm, whereas overall survival was comparable between the two groups during the study period. Conclusions: Induction TPF chemotherapy provided superior tumour response and disease-free survival compared with oral metronomic chemotherapy.
